Controlled and modulated release of basic fibroblast growth factor.

Basic fibroblast growth factor has multivariate effects in stimulating cell growth and the processes that surround tissue repair. Pathophysiologic studies have been hampered by the stability of the compound. Though very potent, basic fibroblast growth factor is rapidly degraded when injected or ingested. Controlled release of basic fibroblast growth factor would allow for examination of the chronic effects of this compound. Conventional matrix polymer-based release devices were fabricated and basic fibroblast growth factor released in a sustained fashion, but 99% of basic fibroblast growth factor mitogenic activity was lost. The source of these losses was identified and preventative measures examined. Preservation and stabilization of basic fibroblast growth factor was accomplished by binding the factor to heparin-Sepharose beads. This permitted prolonged storage, repeated handling, and the encapsulation of basic fibroblast growth factor within a microspherical controlled-release device using a naturally occurring polymer material, alginate. Encapsulation was accomplished with 77% efficiency and 87.5 +/- 12% of the basic fibroblast growth factor was released in a biologically active form. Release activation and regulation was achieved when cleavage of the basic fibroblast growth factor-heparin bonds was enhanced (e.g. by enzymatic bond cleavage with heparinase). Kinetic profiles were identified for a variety of experimental conditions and the effects of the controlled release of basic fibroblast growth factor on BALBc/3T3 fibroblasts examined.

[1]  K. Yoshinaga,et al.  Improvement of in vivo stability of alginate-polylysine capsules. , 1988, The Tohoku journal of experimental medicine.

[2]  E. Edelman,et al.  Biological and biochemical properties of fibroblast growth factors. Implications for the pathogenesis of atherosclerosis. , 1989, Arteriosclerosis.

[3]  R. Langer,et al.  Purification and characterization of heparinase from Flavobacterium heparinum. , 1985, The Journal of biological chemistry.

[4]  Sugamori Me,et al.  Microencapsulation of pancreatic islets in a water insoluble polyacrylate. , 1989 .

[5]  X. Fu,et al.  Microencapsulated parathyroid cells as a bioartificial parathyroid. In vivo studies. , 1989, Transplantation.

[6]  D. Rifkin,et al.  Recent developments in the cell biology of basic fibroblast growth factor , 1989, The Journal of cell biology.

[7]  C. Daniel,et al.  Reversible inhibition of mammary gland growth by transforming growth factor-beta. , 1987, Science.

[8]  J. Folkman,et al.  Basic fibroblast growth factor binds to subendothelial extracellular matrix and is released by heparitinase and heparin-like molecules. , 1989, Biochemistry.

[9]  D. Gospodarowicz,et al.  Isolation of pituitary fibroblast growth factor by fast protein liquid chromatography (FPLC): Partial chemical and biological characterization , 1985, Journal of cellular physiology.

[10]  T. Maciag,et al.  The heparin-binding (fibroblast) growth factor family of proteins. , 1989, Annual review of biochemistry.

[11]  F. Lim,et al.  Microencapsulated islets as bioartificial endocrine pancreas. , 1980, Science.

[12]  M. Klagsbrun.  The fibroblast growth factor family: structural and biological properties. , 1989, Progress in growth factor research.

[13]  N. Ling,et al.  Primary structure of bovine pituitary basic fibroblast growth factor (FGF) and comparison with the amino-terminal sequence of bovine brain acidic FGF. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[14]  G. Labourdette,et al.  Brain basic fibroblast growth factor stimulates the proliferation of rat neuronal precursor cells in vitro , 1987, FEBS letters.

[15]  M. Goosen,et al.  Optimization of microencapsulation parameters: Semipermeable microcapsules as a bioartificial pancreas , 1985, Biotechnology and bioengineering.

[16]  R. Langer,et al.  Polymers for sustained macromolecule release: procedures to fabricate reproducible delivery systems and control release kinetics. , 1980, Journal of pharmaceutical sciences.

[17]  R Langer,et al.  Controlled release and magnetically modulated release systems for macromolecules. , 1985, Methods in enzymology.

[18]  D. Gospodarowicz,et al.  Purification of the fibroblast growth factor activity from bovine brain. , 1978, The Journal of biological chemistry.

[19]  A. Sun,et al.  Microencapsulated hepatocytes for bioartificial liver support. , 1988, Artificial organs.

[20]  Ouer Ra.  Sensitivity to kelcoloid; preliminary study. , 1949 .

[21]  D. Moscatelli,et al.  High and low affinity binding sites for basic fibroblast growth factor on cultured cells: Absence of a role for low affinity binding in the stimulation of plasminogen activator production by bovine capillary endothelial cells , 1987, Journal of cellular physiology.

[22]  R. D. Moss,et al.  Microencapsulation of living cells and tissues. , 1981, Journal of pharmaceutical sciences.

[23]  M. Goosen,et al.  Microencapsulation of crystalline insulin or islets of Langerhans: an insulin diffusion study. , 1983, Artificial organs.

[24]  J. Folkman,et al.  The fate of intravenously administered bFGF and the effect of heparin. , 1989, Growth factors.

[25]  H. Katinger,et al.  Entrapment of animal cells for production of monoclonal antibodies and other biomolecules , 1983, Nature.

[26]  M. Goosen,et al.  Microencapsulated cells as hormone delivery systems. , 1987, Critical reviews in therapeutic drug carrier systems.

[27]  D. Gospodarowicz,et al.  Heparin protects basic and acidic FGF from inactivation , 1986, Journal of cellular physiology.

[28]  M. Klagsbrun,et al.  Purification and assay of intact human basic fibroblast growth factor using heparin-sepharose chromatography , 1986 .

[29]  W. Anderson,et al.  Site-directed neovessel formation in vivo. , 1988, Science.

[30]  N. Ling,et al.  Primary structure of bovine brain acidic fibroblast growth factor (FGF). , 1985, Biochemical and biophysical research communications.